Patents by Inventor Gerald B. Grindey

Gerald B. Grindey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antitumor compositions and methods of treatment
    Patent number: 5565494
    Abstract: This invention provides certain benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier, and processes for preparing the benzenesulfonamide derivatives.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: October 15, 1996
    Assignee: Eli Lilly and Company
    Inventors: Gerald B. Grindey, Cora S. Grossman, J. Jeffry Howbert, Karen L. Lobb, James E. Ray, John E. Toth
  • Method of treating tumors in mammals with 2',2'-difluoronucleosides
    Patent number: 5464826
    Abstract: A method of treating susceptible neoplasms in mammals comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of the formula ##STR1## wherein: R.sup.1 is hydrogen;R.sup.2 is a base defined by one of the formulae ##STR2## X is C-R.sup.4 ; R.sup.3 is hydrogen;R.sup.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, bromo, fluoro, chloro or iodo;and the pharmaceutically-acceptable salts thereof.
    Type: Grant
    Filed: July 26, 1994
    Date of Patent: November 7, 1995
    Assignee: Eli Lilly and Company
    Inventors: Gerald B. Grindey, Larry W. Hertel
  • Antitumor compositions and methods
    Patent number: 5254582
    Abstract: This invention provides the use of N-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3-dihydrobenzofuran-5-sulfonamid e, and pharmaceutically acceptable salts thereof, in the treatment of susceptible neoplasms in mammals. This invention further provides the novel aforementioned compound and its pharmaceutical formulations.
    Type: Grant
    Filed: February 5, 1992
    Date of Patent: October 19, 1993
    Assignee: Eli Lilly and Company
    Inventors: George B. Boder, William J. Ehlhardt, Gerald B. Grindey, John E. Toth, John F. Worzalla, John L. Zimmermann
  • Pyrrolo(2,3-d)pyrimidines
    Patent number: 5248775
    Abstract: 3-Ethynylpyrrolo[2,3-d]pyrimidines are chemical intermediates for antineoplastic N-(acyl)glutamic acid derivatives. A typical embodiment is 3-ethynyl-4-hydroxy-6-pivaloylaminopyrrolo[2,3-d]pyrimidine.
    Type: Grant
    Filed: January 31, 1992
    Date of Patent: September 28, 1993
    Assignee: The Trustees of Princeton University
    Inventors: Edward C. Taylor, Dietmar G. Kuhnt, Chuan Shih, Gerald B. Grindey
  • Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
    Patent number: 5217974
    Abstract: Administration of a folate binding protein binding agent in conjunction with use of an antitumor agent which is an inhibitor of glycinamide ribonucleotide transformylase or other antifolate reduces the toxic effects of such agent and provides an enhanced therapeutic index.
    Type: Grant
    Filed: September 4, 1992
    Date of Patent: June 8, 1993
    Assignee: Eli Lilly and Company
    Inventors: Gerald B. Grindey, Chuan Shih
  • 2-deoxy-2',2'-difluoro-inosine and 5'O-derivatives
    Patent number: 5061793
    Abstract: 2'-deoxy-2',2'-difluoro-inosine and 5'-O alkyl derivatives are disclosed as inhibitors of neoplasms.
    Type: Grant
    Filed: March 3, 1988
    Date of Patent: October 29, 1991
    Assignee: Eli Lilly and Company
    Inventors: Gerald B. Grindey, Larry W. Hertel
  • N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
    Patent number: 5028608
    Abstract: N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]-pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-{5-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)ethyl]thien-2-ylcar bonyl}-L-glutamic acid.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: July 2, 1991
    Assignee: The Trustees of Princeton University
    Inventors: Edward C. Taylor, Dietmar G. Kuhnt, Chuan Shih, Gerald B. Grindey
  • N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
    Patent number: 4996206
    Abstract: N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-[4-(2-{4-hydroxypyrrolo[2,3-d]pyrimidin-3-yl}ethyl)benzoyl]-L-glutamic acid.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: February 26, 1991
    Assignee: The Trustees of Princeton University
    Inventors: Edward C. Taylor, Dietmar G. Kuhnt, Chuan Shih, Gerald B. Grindey